Study guide

35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

Key Takeaways Explain This Topic AI

The Revised Cardiac Risk Index counts high-risk surgery, ischemic heart disease, heart failure, cerebrovascular disease, insulin-treated diabetes and creatinine above 2 mg/dL; patients who can do 4 METs or more usually need no further testing.

Wounds heal through hemostasis, inflammation, proliferation and remodeling; scars reach only about 80% of the original strength.

Prophylactic cefazolin is given within 60 minutes before incision and stopped within 24 hours; hair is removed with clippers, not razors.

Malignant hyperthermia is triggered by volatile anesthetics and succinylcholine (ryanodine receptor mutation) and treated with dantrolene; local anesthetic systemic toxicity is treated with lipid emulsion.

The WHO Surgical Safety Checklist has three pauses: sign in (before anesthesia), time out (before incision) and sign out (before the patient leaves the operating room).

Last updated: October 2026

Why this area matters

The TOS lists:

  • wound healing;
  • surgical infection;
  • asepsis and antisepsis;
  • oncology, immunology and transplantation ;
  • anesthesia ;

patient safety and quality of surgical care .

It also asks you to prepare patients for surgery and plan postoperative care. Surgical site infections, wrong-site surgery and preventable anesthetic complications are avoidable harms, and quality programs target them.

Preoperative Risk Stratification & Cardiac Evaluation

Preoperative assessment seeks to uncover uncompensated systemic disorders, quantify perioperative morbidity, and optimize physiological reserve prior to elective intervention.

Cardiovascular Risk Stratification: The Revised Cardiac Risk Index (RCRI)

Cardiovascular events constitute the leading cause of perioperative mortality following non-cardiac surgery. The Revised Cardiac Risk Index (RCRI) , or Lee Criteria , evaluates six independent clinical predictors of Major Adverse Cardiac Events (MACE):

High-risk surgical procedure: Intraperitoneal, intrathoracic, or suprainguinal vascular surgery.

History of ischemic heart disease: Prior myocardial infarction, positive exercise stress test, current angina, nitrate use, or pathological Q waves.

History of congestive heart failure: Prior pulmonary edema, paroxysmal nocturnal dyspnea, bilateral crackles, S3 gallop, or cardiomegaly on chest radiograph.

History of cerebrovascular disease: Prior transient ischemic attack (TIA) or cerebrovascular accident (CVA).

Preoperative diabetes mellitus requiring insulin therapy.

Preoperative serum creatinine > 2.0 mg/dL > 2.0\text{ mg/dL} > 2.0 mg/dL ( > 177 μ mol/L > 177\text{ }\mu\text{mol/L} > 177 μ mol/L ).

  • Predictors Present Risk Class Estimated MACE Rate Recommended Action
  • 0 Predictors Class I 0.4% - 0.9% Proceed with planned surgery; no advanced testing needed
  • 1 Predictor Class II 1.0% - 1.3% Proceed if functional capacity is good ( > 4 METs > 4\text{ METs} > 4 METs )
  • 2 Predictors Class III 4.0% - 6.6% Non-invasive cardiac stress testing if it alters management
  • ≥ 3 \ge 3 ≥ 3 Predictors Class IV 9.0% - 11.0%+ Formal cardiology evaluation, stress imaging, optimization
  • Functional Capacity: Metabolic Equivalents (METs)

Functional capacity is quantified in Metabolic Equivalents of Task (METs) , where 1 MET = 3.5 mL O 2 /kg/min 1\text{ MET} = 3.5\text{ mL } \text{O}_2\text{/kg/min} 1 MET = 3.5 mL O 2 ​ /kg/min (resting basal oxygen consumption):

Poor functional capacity ( < 4 METs < 4\text{ METs} < 4 METs ): Inability to walk two blocks on level ground or climb one flight of stairs without stopping due to dyspnea or angina. Patients in this category with elevated RCRI scores require preoperative pharmacological stress testing (dobutamine echocardiography or dipyridamole/adenosine myocardial perfusion imaging).

Moderate to excellent capacity ( ≥ 4 to > 10 METs \ge 4\text{ to } > 10\text{ METs} ≥ 4 to > 10 METs ): Ability to climb two flights of stairs, run a short distance, or engage in vigorous sports. Patients demonstrating ≥ 4 METs \ge 4\text{ METs} ≥ 4 METs can safely undergo non-cardiac surgery without further non-invasive testing even in the presence of elevated RCRI factors.

Perioperative Pulmonary and Hepatic Risk

Pulmonary Risk: Chronic obstructive pulmonary disease (COPD), cigarette smoking (stopping at least 4 to 8 weeks before surgery gives the greatest reduction in respiratory and wound complications, but stopping at any time before surgery helps), advanced age, and upper abdominal or thoracic incisions. Incentive spirometry and early post-op ambulation mitigate atelectasis.

Hepatic Risk: Evaluated using the Child-Turcotte-Pugh (CTP) score (Albumin, Bilirubin, INR/PT, Ascites, Encephalopathy) and MELD score. Class A cirrhosis carries ~10% surgical mortality, Class B carries ~30% mortality, and Class C carries > 75 − 80 % > 75-80\% > 75 − 80% operative mortality, representing a relative contraindication to non-emergent elective surgery.

Perioperative Medication Management: Antiplatelet and Anticoagulant Protocols

Balancing the risk of catastrophic intraoperative surgical hemorrhage against devastating thromboembolism (stent thrombosis, stroke, pulmonary embolism) dictates strict adherence to drug withdrawal intervals:

Medication Class Specific Agent Preoperative Cessation Interval Clinical Management & Bridging Rationale

Antiplatelet Aspirin ( 81 to 325 mg 81\text{ to }325\text{ mg} 81 to 325 mg ) Continue or hold 7 − 10 days 7-10\text{ days} 7 − 10 days Continue for secondary prevention in high cardiovascular risk; hold 7 − 10 days 7-10\text{ days} 7 − 10 days only for closed-space surgery (intracranial, spinal canal, posterior ocular chamber)

Antiplatelet (P2Y12 Inhibitor) Clopidogrel (Plavix) 5 to 7 days 5\text{ to }7\text{ days} 5 to 7 days Discontinue 5 days 5\text{ days} 5 days prior. Elective non-cardiac surgery must be deferred 6 months after drug-eluting stent (DES) and 1 month after bare-metal stent (BMS)

Vitamin K Antagonist Warfarin (Coumadin) 5 days 5\text{ days} 5 days Hold 5 days 5\text{ days} 5 days pre-op to allow INR to drop to ≤ 1.4 \le 1.4 ≤ 1.4 . Bridge with therapeutic Low-Molecular-Weight Heparin (LMWH) in patients with mechanical mitral valves or high-risk atrial fibrillation

Direct Oral Anticoagulants (DOACs) Dabigatran, Rivaroxaban, Apixaban 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours Normal renal function: hold 24 − 48 hours 24-48\text{ hours} 24 − 48 hours for low-bleed risk; hold 48 − 72 hours 48-72\text{ hours} 48 − 72 hours for high-bleed risk or impaired renal function. Routine bridging is NOT required

Heparin Bridging Therapeutic Enoxaparin (LMWH) 24 hours 24\text{ hours} 24 hours Last dose given 24 hours prior to surgery; restart 24-72 hours postoperatively once surgical hemostasis is secure

Heparin Bridging Unfractionated Heparin (IV UFH) 4 to 6 hours 4\text{ to }6\text{ hours} 4 to 6 hours Discontinue infusion 4 to 6 hours preoperatively; check aPTT to confirm normalization before incision

Biology of Surgical Wound Healing

Wound healing is a coordinated cellular and biochemical cascade divided into four continuous, overlapping phases:

Hemostasis (Minutes to Hours): Tissue injury exposes subendothelial collagen, initiating the intrinsic coagulation cascade and platelet aggregation. The provisional fibrin-fibronectin clot seals the wound. Degranulating platelets release Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-beta (TGF- β \beta β ) , which act as potent chemoattractants for inflammatory cells.

Inflammation (Day 1 to Day 4):

Neutrophils (First 24-48 hours): First circulating cells to infiltrate; clear bacterial contaminants and devitalized debris via phagocytosis, reactive oxygen species, and proteases.

Macrophages (Day 2 to Day 4): The essential orchestrators of wound healing . Macrophages release critical cytokines (TGF- β \beta β , VEGF, FGF, PDGF) that stimulate angiogenesis, re-epithelialization, and fibroblastic recruitment. Absence of macrophages arrests repair.

Proliferation (Day 4 to Day 21): Characterized by four interdependent events:

Fibroplasia: Fibroblasts proliferate and synthesize ground substance (glycosaminoglycans, proteoglycans) and Type III collagen (immature, thin, non-crosslinked).

Angiogenesis: Vascular Endothelial Growth Factor (VEGF) promotes budding of new capillary loops, producing beefy-red granulation tissue .

Epithelialization: Keratinocytes migrate across the viable wound bed from wound edges and adnexal structures (hair follicles, sweat glands) until contact inhibition occurs.

Wound Contraction: Specialized myofibroblasts containing alpha-smooth muscle actin anchor to extracellular fibronectin and contract the wound margins.

Remodeling / Maturation (Day 21 to 1-2 Years): Type III collagen is systematically degraded by matrix metalloproteinases (MMPs) and replaced by Type I collagen (thick, organized parallel fibrils). Tensile strength rises progressively: 3% at 1 week, 20% at 3 weeks, and plateaus at a maximum of 80% of original unbroken skin strength by 6 to 12 weeks. Wounds never regain 100% tensile strength.

Surgical Wound Classification and Infection Prevention

Surgical Site Infections (SSIs) are classified according to the Centers for Disease Control and Prevention (CDC) operative field contamination scheme:

Wound Class Category Definition & Operative Criteria Clinical Examples Expected SSI Rate

Class I Clean Uninfected operative wound; no acute inflammation encountered; respiratory, alimentary, genital, or uninfected urinary tracts are NOT entered; closed primarily Elective inguinal hernia repair, thyroidectomy, total hip arthroplasty, breast biopsy < 2 % < 2\% < 2%

Class II Clean-Contaminated Operative wound where respiratory, alimentary, genital, or urinary tract is entered under controlled conditions without unusual contamination Elective laparoscopic cholecystectomy, elective appendectomy, elective low anterior resection with bowel prep 5 % − 10 % 5\% - 10\% 5% − 10%

Class III Contaminated Open, fresh accidental wounds; operations with major breaks in sterile technique or gross spillage from the gastrointestinal tract; acute non-purulent inflammation Open appendectomy for suppurative non-perforated appendicitis, penetrating trauma < 4 hours < 4\text{ hours} < 4 hours old, gross bile spillage 10 % − 20 % 10\% - 20\% 10% − 20%

Class IV Dirty / Infected Old traumatic wounds with retained devitalized tissue; established intra-abdominal infection or perforated viscera prior to incision Perforated acute diverticulitis with feculent peritonitis, ruptured appendiceal abscess, pancreatic necrosectomy > 25 % − 40 % > 25\% - 40\% > 25% − 40%

Evidence-Based SSI Prevention Protocols

Antimicrobial Prophylaxis Timing: First-line parenteral antibiotic (typically Cefazolin 2 g 2\text{ g} 2 g IV, or 3 g 3\text{ g} 3 g if weight > 120 kg > 120\text{ kg} > 120 kg ) must be fully infused within 60 minutes prior to surgical incision (within 120 minutes for vancomycin or fluoroquinolones) to establish tissue levels exceeding minimum inhibitory concentration (MIC). Prophylaxis must be redosed if surgery exceeds two drug half-lives ( 3 − 4 hours 3-4\text{ hours} 3 − 4 hours for cefazolin) or blood loss exceeds 1 , 500 mL 1,500\text{ mL} 1 , 500 mL . Prophylactic antibiotics must be discontinued within 24 hours postoperatively.

Hair Removal: Never use razors, which create microscopic dermal abrasions serving as bacterial nidi. If hair interferes with the field, use electric clippers immediately prior to surgery.

Skin Antisepsis: Chlorhexidine-gluconate with alcohol is superior to povidone-iodine.

Physiologic Maintenance: Maintain intraoperative normothermia ( > 36.0 ∘ C > 36.0^\circ\text{C} > 36. 0 ∘ C ), perioperative euglycemia (blood glucose < 180 mg/dL < 180\text{ mg/dL} < 180 mg/dL ), and adequate tissue oxygenation.

Diagnostic Approach to Postoperative Fever: The "5 Ws"

Postoperative pyrexia (temperature ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C or 100.4 ∘ F 100.4^\circ\text{F} 100. 4 ∘ F ) follows a predictable chronologic differential diagnosis governed by the mnemonic "5 Ws":

Wind (Postoperative Days 1-2): Atelectasis & Early Pulmonary Complications

Mechanism: General anesthesia, immobility, diaphragmatic splinting from pain, and decreased tidal volumes cause alveolar collapse in lung bases.

Workup & Management: Chest auscultation reveals decreased breath sounds and bibasilar crackles. Treatment: Incentive spirometry, deep breathing exercises, aggressive pulmonary toilet, adequate multimodal analgesia, and early mobilization. Routine chest radiographs and antibiotics are not indicated for early uncomplicated atelectasis.

Water (Postoperative Day 3): Urinary Tract Infection (UTI)

Mechanism: Associated with indwelling transurethral Foley catheters (Catheter-Associated UTI, CAUTI); bacterial ascent ( Escherichia coli , Klebsiella , Enterococcus ).

Workup & Management: Urinalysis, urine culture and sensitivity. Prompt removal of indwelling catheter; initiate targeted antimicrobial therapy.

Wound (Postoperative Day 5): Surgical Site Infection (SSI)

Mechanism: Bacterial proliferation at incision site ( Staphylococcus aureus , coagulase-negative staphylococci, enteric gram-negative bacilli). Note: Streptococcus pyogenes (Group A Strep) or Clostridium perfringens can cause fulminant, toxic wound infections within 24-48 hours.

Workup & Management: Examine wound bed; look for erythema, induration, warmth, fluctuating fluid collection, and purulent discharge. Management: Suture or staple removal, opening and drainage of the surgical incision, packing with moist gauze, allowing healing by secondary intention. Parenteral antibiotics are reserved for surrounding invasive cellulitis or systemic sepsis.

Walking (Postoperative Day 7): Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE)

Mechanism: Virchow's triad (stasis from bed rest, endothelial vessel injury, perioperative hypercoagulability).

Workup & Management: Unilateral lower extremity swelling, calf tenderness (Homan's sign is unreliable), tachycardia, pleuritic chest pain, acute tachypnea, desaturation. Duplex venous ultrasonography for DVT; CT Pulmonary Angiography (CTPA) for suspected PE. Treatment: Therapeutic anticoagulation (LMWH, unfractionated heparin infusion, or DOACs).

Wonder Drugs & Deep Collections (Postoperative Day 10+):

Mechanism: Drug-induced fever (beta-lactams, sulfonamides, heparin-induced thrombocytopenia, phenytoin) or occult deep surgical complications (intra-abdominal abscess, anastomotic leak, infected seroma/hematoma).

Workup & Management: Contrast-enhanced abdominal/pelvic CT scan to rule out anastomotic dehiscence or fluid collections. Discontinue non-essential offending medications. Percutaneous image-guided catheter drainage of loculated abscesses.

Wound closure and abnormal healing

Types of wound closure:

primary intention : edges closed at once in clean wounds;

secondary intention : left open to heal by granulation and contraction, as in contaminated wounds or abscess cavities;

tertiary intention (delayed primary closure) : left open for 3 to 5 days, then closed if clean, as in contaminated trauma.

Factors that impair healing:

  • infection ;
  • ischemia;
  • diabetes ;
  • malnutrition (protein, vitamin C, zinc);
  • corticosteroids (vitamin A partly reverses their effect);
  • smoking;
  • radiation;
  • chemotherapy;
  • old age;

tension.

Abnormal scars:

hypertrophic scars stay within the wound borders and may regress;

keloids extend beyond the wound borders, are more common in darker skin and on the earlobes, chest and shoulders, and recur after simple excision. Treat keloids with intralesional steroids, pressure and silicone sheets, and excision plus adjuvant therapy.

Chronic wounds (venous, arterial, diabetic and pressure ulcers): treat the cause, debride and offload. A non-healing ulcer in an old scar or chronic sinus may be a Marjolin ulcer (squamous cell carcinoma), so biopsy it.

Surgical infection, asepsis and antisepsis

Sterilization destroys all microbes including spores:

  • steam autoclave , for example 121°C for at least 15 minutes, is the standard for heat-stable instruments;
  • dry heat;
  • ethylene oxide for heat-sensitive items;
  • hydrogen peroxide plasma;

glutaraldehyde as a high-level disinfectant or chemical sterilant for endoscopes.

Disinfection levels: high-level (endoscopes), intermediate and low-level (surfaces). Antisepsis applies to living tissue: chlorhexidine-alcohol, povidone-iodine and alcohol hand rub.

Surgical hand antisepsis and sterile technique (gowns, gloves, drapes, OR traffic control) reduce infection.

Surgical infections:

  • abscesses need drainage ;
  • cellulitis needs antibiotics;
  • necrotizing soft-tissue infections need emergency debridement;
  • intra-abdominal infections need source control plus antibiotics;

hospital-acquired infections include SSI, pneumonia, catheter-associated UTI and central-line infection.

Tetanus prophylaxis for wounds:

for a clean minor wound , give Td or Tdap if the patient has had fewer than 3 doses or the last dose was more than 10 years ago;

for other wounds (contaminated, puncture, crush, burns), give Td or Tdap if the patient has had fewer than 3 doses or the last dose was more than 5 years ago, plus tetanus immune globulin if fewer than 3 doses or unknown history.

Surgical oncology, immunology and transplantation

Diagnosis:

tissue diagnosis by fine-needle aspiration , core needle biopsy , incisional biopsy (part of a large mass) or excisional biopsy (the whole lesion);

sarcomas and limb masses are biopsied along the line of the future incision.

Staging: TNM staging (tumor size and invasion, nodes, metastasis) guides treatment and prognosis. Grading describes differentiation.

Principles of oncologic resection:

  • en bloc removal with clear (R0) margins ;
  • removal of the regional nodes or sentinel lymph node biopsy (breast cancer, melanoma);

avoiding tumor spillage.

Multimodal therapy:

  • neoadjuvant treatment (before surgery) to shrink tumors, as in rectal, breast and esophageal cancer;
  • adjuvant therapy (after surgery) to treat micrometastases;

palliative surgery for obstruction or bleeding.

Tumor markers monitor recurrence: CEA, AFP, CA 19-9, CA-125, PSA, calcitonin, hCG.

Transplant immunology:

HLA matching and crossmatch reduce rejection;

hyperacute rejection occurs within minutes from preformed antibodies (ABO or HLA) and is prevented by crossmatching;

acute rejection occurs in weeks to months, is mainly T-cell mediated and is reversible with steroids;

chronic rejection occurs over months to years with fibrosis and vasculopathy and is irreversible.

Immunosuppressants:

  • calcineurin inhibitors (tacrolimus, cyclosporine): nephrotoxicity, hypertension, tremor;
  • mycophenolate: myelosuppression;
  • corticosteroids;
  • mTOR inhibitors;

induction antibodies.

Risks are opportunistic infections (CMV) and cancers (skin cancer, post-transplant lymphoproliferative disorder).

Organ donation follows RA 7170: brain death determination and informed consent. Commercial organ trade is prohibited.

Anesthesia

ASA physical status:

  • I: healthy;
  • II: mild systemic disease;
  • III: severe systemic disease;
  • IV: severe systemic disease that is a constant threat to life;
  • V: moribund;
  • VI: brain-dead organ donor;

"E" is added for emergencies.

Fasting before elective surgery: clear fluids up to 2 hours , breast milk 4 hours, a light meal or formula 6 hours, a heavy meal 8 hours.

Airway assessment: Mallampati class, mouth opening, neck mobility. Prepare for a difficult airway.

Drugs for general anesthesia:

propofol : hypotension, antiemetic;

ketamine : maintains BP and airway reflexes, bronchodilator, causes emergence reactions; useful in shock and asthma;

  • etomidate : cardiovascularly stable, causes adrenal suppression;
  • volatile agents (sevoflurane, isoflurane);
  • opioids;

neuromuscular blockers : succinylcholine (depolarizing, fast onset) causes hyperkalemia in burns, crush injury, denervation and immobilization after the first days, and is a trigger for malignant hyperthermia. Non-depolarizing blockers (rocuronium) are reversed with neostigmine or sugammadex .

Malignant hyperthermia:

  • an inherited ryanodine receptor (RYR1) disorder triggered by volatile anesthetics and succinylcholine ;
  • rising end-tidal CO2, masseter rigidity, tachycardia, hyperthermia, hyperkalemia, acidosis and rhabdomyolysis;

treat by stopping the trigger, giving dantrolene , cooling and correcting hyperkalemia.

Regional anesthesia:

  • spinal anesthesia (subarachnoid) is fast and dense, and causes hypotension and post-dural puncture headache;
  • epidural anesthesia can be continued for postoperative analgesia;

check coagulation first, because of the risk of epidural hematoma.

Local anesthetics:

maximum lidocaine dose is about 4.5 mg/kg plain or 7 mg/kg with epinephrine ; bupivacaine about 2.5 mg/kg (cardiotoxic);

local anesthetic systemic toxicity causes perioral numbness, tinnitus, seizures, arrhythmias and cardiac arrest. Treat with airway support, seizure control and 20% lipid emulsion ;

epinephrine-containing solutions are used with caution in end-arteries.

Patient safety and quality of surgical care

WHO Surgical Safety Checklist:

sign in , before induction: identity, site, consent, site marking, anesthesia check, allergies, airway and aspiration risk, risk of blood loss;

time out , before incision: team introductions, confirm patient, site and procedure, antibiotic prophylaxis given, anticipated critical events, imaging displayed;

sign out , before the patient leaves the room: procedure recorded, instrument, sponge and needle counts correct , specimen labeling, equipment problems, recovery concerns.

The checklist lowers complications and deaths.

Never events: wrong-site, wrong-procedure and wrong-patient surgery, and retained foreign objects . Prevent them with site marking, time-outs and counts.

Quality measures:

  • surgical site infection rates;
  • morbidity and mortality conferences ;
  • clinical audit and outcome tracking;
  • VTE prophylaxis;
  • informed consent;
  • teamwork and communication (structured handoffs such as SBAR);
  • ERAS pathways;

a culture of reporting errors without blame.

Loading diagram... Chronological Evaluation and Management of Postoperative Fever (The 5 Ws)